Dorman Products, Inc. (DORM) Hit a 52 Week High, Can the Run Continue? — Positive
DORM Zacks Investment Research — September 09, 2025Dorman Products (DORM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Frontdoor Inc. (FTDR) Hit a 52 Week High, Can the Run Continue? — Positive
FTDR Zacks Investment Research — September 09, 2025Frontdoor (FTDR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
BRP Inc. (DOOO) Hit a 52 Week High, Can the Run Continue? — Positive
DOOO Zacks Investment Research — September 09, 2025BRP (DOOO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
RTX's Pratt & Whitney Canada selected by Clean Aviation to lead PHARES hybrid-electric propulsion consortium — Neutral
RTX PRNewsWire — September 09, 2025Selection marks the first time a Canadian company will participate in and lead a Clean Aviation program LONGUEUIL, Quebec , Sept. 9, 2025 /PRNewswire/ -- Pratt & Whitney Canada, an RTX business, has been selected by the European Union's Clean Aviation Joint Undertaking (Clean Aviation) to lead the Powerplant Hybrid Application REgional Segment (PHARES) project.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics — Neutral
CAPR Business Wire — September 09, 2025NEW YORK--(BUSINESS WIRE)---- $CAPR #CAPR--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On July 11, 2025, Capricor issued a press re.
Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript — Neutral
ARVN Seeking Alpha — September 09, 2025Arvinas, Inc. (NASDAQ:ARVN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants John Houston - Chairperson, CEO & President Noah Berkowitz - Chief Medical Officer Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Senior Equity Analyst All right, everyone. I think we'll get started here with the afternoon session.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven — Neutral
BHVN Business Wire — September 09, 2025NEW YORK--(BUSINESS WIRE)---- $BHVN #BHVN--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On May 14, 2025, Biohaven issued a press release “announc[in.
ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell? — Positive
ALVO Zacks Investment Research — September 09, 2025Alvotech trades near a 52-week low after a 38% drop in 2025, but soaring revenues and new biosimilar approvals highlight its growth path.
CASY Q1 Earnings & Revenues Beat Estimates, Inside Sales Up 14.2% Y/Y — Positive
CASY Zacks Investment Research — September 09, 2025Casey's delivered a strong first quarter with earnings and revenue beats, boosted by 14.2% inside sales growth and margin expansion.
Lantheus Holdings, Inc. (LNTH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript — Neutral
LNTH Seeking Alpha — September 09, 2025Lantheus Holdings, Inc. (NASDAQ:LNTH ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:00 AM EDT Company Participants Robert Marshall - CFO & Treasurer Brian Markison - CEO & Director Presentation Unknown Analyst Thank you all for coming. Welcome to the Morgan Stanley Healthcare Conference.
89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript) — Neutral
ETNB Seeking Alpha — September 09, 202589bio, Inc. (NASDAQ:ETNB ) Cantor Global Healthcare Conference 2025 September 4, 2025 11:30 AM EDT Company Participants Rohan Palekar - CEO & Director Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Presentation Steven Seedhouse MD & Biotechnology Analyst Well, welcome, everyone, and it's really a privilege for me to introduce our next participating company at the Cantor Global Healthcare Conference. First time Steve Seedhouse from the biotech team.
Google admits the open web is ‘in rapid decline' — reversing earlier claim that traffic is ‘thriving' — Negative
GOOG GOOGL New York Post — September 09, 2025The disclosure surfaced in a filing last week in the government's ongoing antitrust case against Google.
Bank Of Montreal (BMO:CA) Presents At Barclays 23rd Annual Global Financial Services Conference Transcript — Neutral
BERZ BMO Seeking Alpha — September 09, 2025Bank of Montreal (TSX:BMO:CA ) Barclays 23rd Annual Global Financial Services Conference September 9, 2025 7:30 AM EDT Company Participants Tayfun Tuzun - Chief Financial Officer Conference Call Participants Brian Morton - Barclays Bank PLC, Research Division Presentation Brian Morton Research Analyst Good morning. Welcome to day 2 of the Barclays Global Financial Services Conference.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience — Neutral
ANRO Business Wire — September 09, 2025NEW YORK--(BUSINESS WIRE)---- $ANRO #ANRO--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On October 22, 2024, Alto issued a press release annou.
RTX Wins $205M Contract for Radar-Guided Gun: Buy the Stock Now? — Neutral
RTX Zacks Investment Research — September 09, 2025RTX secures a $205M Phalanx CIWS contract, adding to its $92B defense backlog, but supply-chain risks and premium valuation urge caution.
Salesforce Rises 8% in Three Months: Should You Buy CRM Stock Now? — Positive
CRM Zacks Investment Research — September 09, 2025CRM stock climbs as AI integration, solid earnings and discounted valuation fuel investor confidence.
Rivian (NASDAQ: RIVN) Price Prediction and Forecast 2025-2030 for September 9 — Neutral
RIVN 24/7 Wall Street — September 09, 2025Shares of Rivian Automotive (NASDAQ:RIVN) lost 0.73% over the past five trading sessions after gaining 3.43% the five prior.
Detroit Lions Offense To Drive Philanthropic Gains Through Comerica First Down Program — Neutral
CMA PRNewsWire — September 09, 2025Lions and Comerica Bank team up for ninth season to assist community partners' impact on Metro Detroit DETROIT , Sept. 9, 2025 /PRNewswire/ -- Powered by one of the NFL's most dynamic offenses in recent seasons, the Comerica First Down Program partnership with the Detroit Lions returns for a ninth year to assist eight Metro Detroit community organizations throughout the 2025 regular season.
Zeta Global Holdings Corp. is benefiting from powerful secular trends in AI and digital advertising, with strong financial performance and robust growth prospects. The company's proprietary data model and evolving privacy regulations provide a competitive edge, while upcoming events may act as catalysts. ZETA stock valuation remains compelling, with Wall Street targets far above current prices, low debt, and conservative P/S and P/E ratios supporting upside.
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer — Neutral
TLSA GlobeNewsWire — September 09, 2025BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 14,848 shares of Tiziana common stock at a price of $1.65 per share in the open market, correcting todays earlier press release. This brings his current purchased shares total to 193,848.